The US FTC issues a FY 2017 report on branded drug firms’ patent settlements with generic competitors

FTC Staff Issues FY 2017 Report on Branded Drug Firms' Patent Settlements with Generic Competitors* The number of reverse-payment agreements remains low; for the first time since FY 2004, no agreement contains a no-AG commitment. According to a new FTC staff report, the total number of final Hatch-Waxman patent settlements entered by pharmaceutical companies in FY 2017 was close to the record high in FY 2016. Despite the high number of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Federal Trade Commission, The US FTC issues a FY 2017 report on branded drug firms’ patent settlements with generic competitors, 3 December 2020, e-Competitions December 2020, Art. N° 98294

Visites 148

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues